This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
MMSI Stock Likely to Gain From Cook Medical's Product Portfolio Buyout
by Zacks Equity Research
Merit Medical expects to solidify its foothold in the underpenetrated global lead management market via the latest asset acquisition.
Merit Medical Stock Falls Despite Positive WRAPSODY Trial Results
by Zacks Equity Research
MMSI announces 6-month results from its WRAPSODY WAVE trial, showing superior efficacy in extending AV fistula patency for dialysis patients.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merit Medical Gains 26.4% Year to Date: What's Driving the Stock?
by Zacks Equity Research
MMSI's shares gain on the back of strength in its Cardiovascular segment and a robust product portfolio.
Why Is Henry Schein (HSIC) Up 5.6% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in Store for Cooper Companies (COO) in Q3 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.
Broad Portfolio to Aid Patterson Companies' (PDCO) Q1 Earnings
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments on the back of comprehensive product offerings.
Merit Medical (MMSI) Q2 Earnings & Revenues Beat, '24 View Up
by Zacks Equity Research
Merit Medical's (MMSI) second-quarter results reflect growth in earnings and revenues. Operating margin expands.
Merit Medical (MMSI) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Merit Medical (MMSI) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Merit Medical (MMSI) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 4.55% and 0.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
BDX vs. MMSI: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BDX vs. MMSI: Which Stock Is the Better Value Option?
Cardinal Health (CAH) Recalls Kits Containing Shenli's Syringes
by Zacks Equity Research
Cardinal Health (CAH) recalls its procedure kits that contain plastic syringes manufactured by a Chinese manufacturer, Jiangsu Shenli.
Merit Medical (MMSI) Inks Deal to Boost Endoscopy Portfolio
by Zacks Equity Research
Merit Medical's (MMSI) latest asset acquisition is likely to expand its endoscopy portfolio with a minimally-invasive solution for GERD patients, thereby improving patient outcomes.
Merit Medical (MMSI) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.
Three Reasons to Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Here's Why Merit Medical (MMSI) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merit Medical (MMSI) Recalls Syringes Made by Jiangsu Shenli
by Zacks Equity Research
Merit Medical (MMSI) recalls certain products containing syringes made by a Chinese manufacturer, Jiangsu Shenli.
Here's Why Merit Medical (MMSI) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Merit Medical (MMSI) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merit Medical (MMSI) Up 5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Merit Medical (MMSI) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Three Reasons to Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Merit Medical's (MMSI) Latest Launch to Boost Patient Care
by Zacks Equity Research
Merit Medical's (MMSI) latest offering is likely to create an efficient approach to inflation, thereby providing improved patient care.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merit Medical (MMSI) to Expand Product Suite Via New Launch
by Zacks Equity Research
Merit Medical's (MMSI) latest additions to its embolotherapy portfolio are likely to improve the patient experience.